Funding a delayed project- from loss making to profit making project Finance strategies & considerations Assignent Sample

1.0 Introduction to :Funding A Delayed Project- From Loss-making To Profit-making Project Finance Strategies And Considerations

Delays in executing the projects often translate to loss in terms of money. Hence, a company must come up with strategic ways to turn such ventures from losing portfolios to profitable ones. This report is on one such delayed project that has led to negative cash flow and has reduced profitability on the overall scale of things. The chief tools here are NPV and cash flow analysis; principally aimed at detailing ways to regain profitability for the project.

The severity of the financial problems of delayed projects cannot be overstated. Delays create higher operational costs and reduce revenue while causing loss of investor confidence. A negative NPV means that, in its current state, the project is destroying value rather than creating it. Thus, the objective of this report is to seek methods under cost-cutting, operational improvements, and seeking other funding to change the situation around.

The report would be structured to present an in-depth analysis of the current financial scenario of the project, its challenges, and the strategies required to move from a loss-making phase to a profit-making one. It would include assessments of financial risks, potential revenue opportunities, and some relevant funding avenues. Furthermore, there will be an extremely focused case study that deals with the NPV calculation and factors affecting such a calculation so that the possibility of any project recovery can be clearly highlighted.

This report is to chart a financial plan towards overcoming project delays. With appropriate structured financial planning, there lies a possibility of not only breaking even but garnering long-term profitability - thereby changing the financial face of the project altogether.

Need a Quick Solution? Professional Assignment Help in the UK with Free Study Resources!

Part ONE: Critical Analysis

1.1 Innovation

On innovative solutions of the software, the presence of focus is noticed of TechInnovate Ltd, particularly its AI-Diagnostix project. This demonstrates its commitment to innovation. This diagnostic tool that is driven by AI has the effectiveness to revolutionize the sector of healthcare through the accuracy of diagnostic enhancement, human error reduction, and speeding the process of making decisions in hospitals. In healthcare, innovation, particularly through AI, or Artificial Intelligence is recognized in the form of a disruptive force that can decrease costs majorly, and improve care to the patient.

The innovation of TechInnovate aligns with the theory of disruptive innovation that is proposed by Clayton Christensen. In the form of technologies, the presence of disruptive innovations is noticed that start by serving niche markets, or offering alternatives that cost lower, and reshape eventually whole industries (Carmody and Wainwright, 2022). Although AI-Diagnostix is still in the development phase, but it targets a niche in healthcare diagnostics by focusing on providing more accurate, faster, and cost-effective tools for diagnostics. Because of this, traditional methods become obsolete majorly. However, delays are experienced by this company, and overruns of cost. This highlights the challenges that are inherent in innovation pioneering.

1.2 Drivers of change

Change in any industry is driven by both external, and internal factors, and this is specifically true for technology companies of the healthcare d TechInnovate. A major internal driver is the overruns of cost, and delays in the AI-Diagnostix development, which put the health of finance of the company at risk (Griffith and Naqvi, 2020). With operating expenses exceeding revenue by £1.5 million in 2023, the company either needs to improve its processes or secure additional funding for the project continuation. These pressures of finance force this company to reconsider its strategies of operation, staffing, and practices of management of projects. 

Eventually, stringent standards of compliance and regulatory hurdles are important drivers of change. In the sector of healthcare, any new technology must pass rigorous checks of regulations to ensure it meets efficacy and safety standards (Müller et al. 2022). For AI-Diagnostix, this indicates adhering to strict guidelines from regulatory bodies d UK Medicines, and MHRA, or Healthcare Products Regulatory Agency, or EMA, or European Medicines Agency. These external forces create delays but are important to ensure the market readiness and legal compliance of the product.

1.3 Operations and Processes

The operational process of TechInnovate, specifically in AI-Diagnostix project management, faces major challenges. Its initial budget is exceeded by this company of £5 million, by spending £7 million. An additional £3 million is required by it for the project completion. These difficulties in finance point to the allocation of resources, and management of project inefficiencies. One of the issues that is primarily present might lead to the absence of robust management strategies that could have identified major challenges regarding regulations, and major challenges regarding regulation earlier.

For these challenges addressing, the implementation can be done by TechInnovate regarding the Lean methodology, which focuses on improving efficiency, and waste reduction in processes (Khianthongkul and Bunyavejchewin, 2024). Through the Lean approach adoption, the identification can be done by the company regarding the non-value-adding activities, and eliminate them, by increasing the speed of the timeline of the project and reducing costs. JIT, or Just-in-time production, is another principle regarding Lean, which can help TechInnovate to ensure the allocation of resources exactly at the time of need. The overspending is prevented through this.

1.4 Research design

The design of the research of TechInnovate for AI-Diagnostix development includes an applied, and explanatory combination of research. New advancements in technology are helped to be understood through exploratory research in machine learning, and AI. On the other side, the focus of the applied research is noticed on the way these technologies can be utilized for particular problems regarding health solving.

In terms of the complexities of regulations in healthcare, clinical trials need to be conducted by this company, and data gathering is needed to be done on the safety, and efficacy of AI-Diagnostix (Bulman et al. 2022). These trials needed a rigorous design regarding research, which includes RCTs, or randomized controlled trials, and observational studies. Collaboration is needed by this company with medical professionals, and hospitals for real-time data collection on the performance of the tools in clinical findings.

1.5 Data Analysis

1.5.1 NPV and Cash Flow Analysis

Figure 1: Projected Cash flow

(Source: self-created in MS EXCEL)

With a Net Present Value of £5541493 AI-Diagnostix is financially feasible for the organization. The positive NPV indicates that the project will enhance the worth of TechInnovate Ltd., way beyond £3 million investment. The projections to the yearly cash flows are increasing year by year from £ 1, 5 million in 2026 up to £ 3, 5 million in 2030 due to the market demand and constant revenues (Hebous, et al. 2022). This up sweep in cash flows is more inviting than the simple profits, which confirm profitability but more importantly, the upward motion757 means that the returns are intensifying over time. Not only did the cost estimates prove accurate with costs totaling $1,350,000, but the calculated NPV proved to be quite large at over $628,200, which increases the ‘measure of robustness’ (Rishad 2020). In all, NPV and cash flow forecasting confirm that AI-Diagnostix should go ahead and seek funding to deepen TechInnovate Ltd’s value proposition, thus transform the organization from a loss-making setup to a profitable one.

1.5.1.1 Feasibility in finance and innovation

In the form of an innovative product, the presence of AI-Diagnostix is noticed, and this has a major potential regarding the industry of healthcare disruption. The NPV or Net Present Value of the project of £5541493 indicates majorly that it is feasible financially and signals a return on investment that is impressive, and far beyond the £3 million additionally, which is needed to bring the completion of the product (Mukherjee 2022). The yearly cash flow increase, in terms of growth, is projected from £1.5 million to £3.5 million, from 2026 to 2030. This shows the robust demand for tools of AI-based diagnostic in the sector of healthcare.

AI, or Artificial Intelligence is leveraged through the innovative product, for the accuracy of diagnostic improvement. This reduces the results' delivery time and professionals in healthcare are supported by it in making major decisions. The viability of finance of AI-Diagnostix is tied closely to its nature of innovation, which addresses major challenges in healthcare. This includes the requirement for more precise, and faster diagnostics (Vasudevan 2022). The AI-Diagnostix ability for the outcomes of healthcare transformation is noticed, at the time of increased revenue generation over time. This makes it more attractive than traditional technologies. This happens because of the compounding innovation value, which enhances both societal impact, and financial returns throughout the years.

1.5.1.2 Role of Innovation in projections of Cash flow and NPV

The feasibility of finance is demonstrated through the positive NPV, and it highlights also the way, innovations can drive the long-term sustainability of finance. Innovative products d AI-Diagnostix offer major returns, because they create often new markets, and define again what are existing already. An example of this is, that AI diagnostics has the potential to majorly reduce healthcare delivery costs through routine task automation, which increases the efficiency of operations in clinics, and hospitals.

The increase in the cash flow is projected from £1.5 million to £3.5 million from 2026 to 2030. This shows the way demand in the market for AI-driven diagnostics will continue to increase as the industry of healthcare adopts majorly these technologies. The increasing demand can be attributed to evolutions that are happening continuously in the technology of AI (Baliouskas et al. 2023). This improves the capabilities of the product, and its relevance is increased in this regard, in the market. In addition to that, in algorithms of machine learning the innovations will enhance the usability, and accuracy of AI Diagnostics. This is driving further the demand, and increasing projections of revenue. 

The constant revenue growth confirms the recognition of the market of AI-Diagnostix in the form of an innovative solution that meets the important needs. The market share, and profitability both get driven through this. As the industry of healthcare gets more driven to data, at that time clinics, and hospitals will want to do AI-based tools integration. By doing this, TechInnovate Ltd positions itself in the form of a leader in innovation in healthcare. The upward trend continuously in cash flow demonstrates the way innovation provides a temporary competitive advantage and also creates a sustainable future in terms of finance.

1.5.2 Present NPV and IRR Figures:

Figure 2: NPV and IRR

(Source: self-created in MS EXCEL)

Internal Rate of Return (IRR): The actual IRR calculated is also very high standing at 69.7% this means that the project is expected to be very profitable. This rate is a lot higher than the normal hurdle rates of investment projects that stand between 10% and 20%. The high IRR suggests that:

The company should focus more on a given project where returns seem to justify investment if the company can spare more resources to complete it in a shorter time.

Nevertheless, the level of such a high IRR also means the corresponding high risk is involved in the project. The company should:

The sensitivity test may be conducted to show the impact of significant variables such as the volume of sales, the price of a product on the rate of IRR (Ejiro, and OMOILE, 2023).

1.5.2.1 Innovation and high IRR

The IRR is determined at 69.7% for the project of AI-Diagnostix, and it is high majorly. This surpasses the typical rates of a hurdle for projects of investment. Between 10% to 20% this ranges generally. This high IRR indicates that the project is viable financially, and also has the potential to be profitable highly for Techlnnovate Ltd. A major innovation is represented through AI-Diagnostix in the technology of healthcare, specifically because AI, or Artificial Intelligence is leveraged through it for the process of diagnostic improvement (Islam et al. 2022). These innovations typically generate higher than average returns, because new value propositions are created by them, and new markets are opened in this regard. 

In terms of AI-Diagnostix, the attribution of high IRR can be done to the disruptive potential of AI in the industry of healthcare. By enhancing, and automating the process of diagnostic, AI-Diagnostix reduces the required time for doctors to make major decisions. This improves the accuracy of diagnostics, and costs are lowered for providers of healthcare while improving the outcomes of patients (Junaid et al. 2024). The ability to address major pain points of industry ensures a strong product demand, which leads to high projected growth in revenue, and high IRR. 

The high IRR also demonstrates the innovative project's scalability. Once the investment in the initial stage is made, at that time, tools that are based on AI d AI-Diagnostix can be rolled out throughout many facilities of healthcare with relatively low marginal costs. This is driving the growth of revenue without a corresponding increase in expenses. The factor of scalability is a major reason, because of why many technological innovations d AI tend to yield high IRRs. 

1.5.3 Payback period

Figure 3: Payback period

(Source: self-created in MS EXCEL)

Payback Period: A payback period of 2.7 years is short as compared to other major R & D project in healthcare technology industry. This quick payback is advantageous because:

It minimizes the associated risks of the project, because the initial costs for its implementation are paid quite quickly (Szyszczak 2024). It can make the project more appealing to risk averse investors or lenders as the downside is limited by certification. It enables TechInnovate Ltd. to start sharing profits with other projects or other improvements at an earlier time.

1.5.3.1 Advantages of a Short Payback Period in Healthcare Technology R&D

Securing funding, engaging regulatory experts, and improving operations early are important for TechInnovate’s AI-Diagnostix project transformation from a loss-making venture to a profitable success. 

At 2.7 years, the payback period is determined, which is majorly short for an important project of R&D in the industry of healthcare technology. This offers many major advantages, specifically in innovation fostering (Tokel 2022). The payback that is happening rapidly minimizes the related risk by ensuring that, regarding the project, the initial costs are quickly recovered. On ROI, or Return on Investment, a swift return enhances the stability in finance but reduces also the unforeseen challenges, and market fluctuations exposure. 

For risk-averse lenders or investors, a short period of payback can be appealing specifically. The downside is limited in this regard, and it is created by quicker recovery of cost, which makes it easier for stakeholders to commit to funding. They are reassured in this regard, that their capital will be promptly returned. Further innovations can spur through confidence, which allows TechInnovate Ltd to implement, and explore effective solutions that might have been deemed too risky in a scenario of longer payback. [Referred to appendix 2]

1.5.4 Break-Even Analysis

Figure 4: Break even calculation

(Source: self-created in MS EXCEL)

Breakeven Point: If looked at the DATA given in the table, it very evidently depicts that the breakeven point for TechInnovate Ltd.is at 445 units i.e.,RIEND annual licenses to hospitals. At this level of volume the company will only make £2,500 of profit which gives the company the capability to meet all fixed and variable costs.

Sensitivity: The company makes a loss when the operations are below 445 units. For instance, it is a loss if you are at 400 units; the company is then likely to lose £200,000. Profitability is sharply higher above 445 units and it shows that the company needs to increase the number of units to make the business more effective and profitable (Mukherjee et al. 2020). For instance, when the number of products sold is 500, the profit obtained is £250,000, whereas if the number of products sold is 600 the profit rises to £700,000.

Revenue and Cost Behavior: The table also shows that the total revenue rises in a straight line with every increment in number of units sold. Variable costs also vary directly with sales but, they do so at a lesser slope than that of the revenue line (Carver 2023). They are costs whose value does not depend on the quantity of products manufactured or the number of services provided.

Profit Potential: This means that once the business has reached the breakeven point, every incremental sale will lead to a new increment in profit. The per unit contribution margin (£4,500) is high, and proves high margin of profit at higher sales levels.

Risk Assessment: The breakeven point of 445 units can be easily messaging to the sales team as it’s a goal to strive for. It also highlights the risk: if the cars below this number are sold, then they make losses within a short span of time.

Pricing Strategy: The contribution made by each unit (£4,500) is very high for a chocolaty product which means that there is a lot of scope to play around with the price (Prathapagiri and Upadhayay, 2023). On the other hand, if the throughput has been high then a slight rise in price is likely to have a large impact on the business profitability (Mukherjee, 2022).

Cost Management: A significant amount of fixed costs is identifiable in the case of prolonged operating hours and high initial capital expenditure of £2,000,000 Offers efficient production mechanisms and sensitive cost control (Kannan 2023). If fixed costs were to decrease, the breakeven point would be lower and thus risk would be decreased (Rishad, 2020).

1.5.4.1 Strategy of Profitability and Breakeven Analysis for TechInnovate Ltd

For TechInnovate Ltd, the breakeven point is present at 445 in terms of annual licenses that are sold. In this regard, earning is done by the company of £2500 in profit. All variable costs and fixed costs are covered in this regard. Below this threshold, losses can be major, which highlights the increasing volume of sales, which is important for profit. This high contribution margin in each unit of £4500 indicates a strong potential for profit as sales increase (Papko and Kozarzewski, 2020). The innovation emphasizing in offerings of products, and strategies of pricing can enhance further the revenue. Through the advanced technologies leveraging, and efficient mechanisms of production, this company can decrease its breakeven-point, but adapt also to the demands of the market. The profit is driven through this, and risks are reduced in this regard. [Referred to appendix 3]

1.5.5 ROI and Performance metrics

Figure 5: ROI and performance metrics

(Source: self-created in MS EXCEL)

The delays related to AI-Diagnostix have caused significant overrun of budget and need further funding. Any internal or external investor will ask for assurance about financial viability before pumping in further resources. In this regard, the financial projection submitted shows that revenues will increase from £3 million in 2023 to £7 million in 2025 along with net profit from £700,000 to £2.3 million. This increases to 76.67% in 2025 and shows a very strong promise of profitability. The overall Net Present Value with the short payback period of 2.7 years ensures that such a project is going to generate positive returns within an almost short time frame, hence becoming an attractive investment.

1.5.5.1 Viability of finance and potential of growth of AI-Diagnostix 

The projections of finance of AI-Diagnostix, indicate that the revenue growth happened from £3 million to £7 million from 2023 to 2025, with a net profit increase from £700000 to £2.3 million. This highlights a major trajectory with a 76.67% margin of profit by 2025. For profit, the strong potential, combined with a short period of payback of 2.7 years, makes the project specifically appealing to investors (Westbrook 2020). Moreover, on the innovation within AI-Diagnostix, the focus enhances its proposition of value, as in diagnostic technology advancements can lead to better operational efficiencies and patient outcomes. Growth is driven further through this, and sustained return on investment is ensured in this regard. [Referred to appendix 4]

Table 1: Force Field Analysis for AI Innovation Project

(Source: self-created in MS EXCEL)

Force Field Analysis is a critical model to analyze the driving forces and restraining forces in the process of the success of the AI diagnostic tool innovation project at TechInnovate Ltd. This tool aids in determining the forces which have a positive impact, if any, on the achievement of the project goals and the forces which act as a barrier. The key driving forces which can be identified includes the possibility to earn large amounts of money through the use of the AI tool and expected to be £ 1.5 million annually (Astuti 2024). Arguments supporting this innovation include an argument that this tool is in line with the trends that dominate the healthcare industry and that the integration of AI into diagnostics, which the tool provides to other organizations, enables them to get a competitive edge. However, as with any medical device, regulatory approval can be a hurdle, yet it also brings the opportunities for a new market, which will increase the future possibilities for the growth of the company.

However, the key limitations are quite evident in the form of restraining forces, which pose compelling obstacles to the project. The main challenge of using the product is the initial cost/value ratio that ranges at £3 million; this capital-intensive approach is feasible when compared to the technical challenges of the project that may slow down or even hinder the project. Lack of commitment from different sections of the organization may also affect the project because some employees may not want change due to the arrival of new AI processes. Thus, the regulatory uncertainty could negatively affect the deployment of the tool to ultimately lead to increased time and cost implications (Irtyshcheva et al. 2022). Consequently, by balancing such force the TechInnovate Ltd. shall be in a position to engage in the following actions/inactions so as to strengthen the driving forces and weaken the restricting forces. For strengthening the driving forces- continue to encourage and support cultural changes that support innovation, provide technical support for development of innovations and engage the regulatory agencies.

Table 2: Change Kaleidoscope Analysis for AI Innovation Project

(Source: self-created in MS EXCEL)

The Change Kaleidoscope provides a solid theoretical lens to analyze the background circumstances that make a difference in the successful application of the AI innovation at TechInnovate Ltd. This means that through exploration of dimensions including time, scope, capability and readiness, the model contributes towards defining a strategic perspective towards change management (Wilkins 2020). This is a timely project; any delay that may be incurred in the approval process, or the actual disengagement of internal resistance could severely erode the competitive edge of the AI tool in the growing healthcare market. Also, change affects many areas and departments, and to a broad circle of employees by its nature, which means that the spectrum of change is wide.

As for the capability, TechInnovate Ltd. has technical knowledge to develop the AI tool However, it lacks sufficient knowledge about the laws and regulation of the countries it may need expert help from outside. The research also reveals that the firm has a moderate internal change management capability, though it is compensated by the operational risk at £25,000 per year. Consequently, the senior management needs to give enough resources and training to the needs of the project to offer a successful implementation (Chua 2023). The general adoption level of the organization is moderate in terms of its willingness to employ AI technologies and it is expected that there will be certain limited resistances which may hinder the advancement of the said technology within the organization. Last but not least, the organizational power structures that see most decision-making processes firmly within the purview of senior leaders should be complemented with effective stakeholder engagement coming from technical, operational, and regulatory departments. In this case, by applying the Change Kaleidoscope, TechInnovate Ltd. can use all four Change Kaleidoscope lenses and manage a change initiative within a clearer framework to alter the company’s resource, capability, and organizational culture settings for a swift transition to the AI-driven model. [Referred to appendix 1]

Part TWO: Evaluation and Recommendation

2.1 Evaluation

2.1.1 Critical Analysis and Calculations for tools and framework

Addressing the Situation:  The NPV calculation directly addresses TechInnovate Ltd.’s issue – a loss making firm that wishes to enter a profitable AI project. £3,000,000 is an investment to support innovative activities, and the analysis of cash flows demonstrates the potential financial consequences of the innovative project.

Innovation Focus:  AI-Diagnostix project is a clear example of how the disruptive innovation is being implemented in the health sector (Hildyard 2021). The case of this innovation financial evaluation establish how this innovation is anticipated to foster increased revenues from £2,500,000 in year one to £4,500,000 in year five good illustration of the effects of good innovation.

Research and Evidence: It tends to focus on investigations with main individuals and the utilization of facts to correct declaration. Projections used in NPV have to be derived from market research, key stakeholder interviews, industry research among other activities (Hermes and Lensink, 2020). The increasing annual revenue to be included in the formula should however, provide some statistical backing on trends in the take-up rate of AI in the health sector.

Tools and Frameworks: Used in this valuation were the NPV, IRR and the Payback Period. In addition to these, it should incorporate other innovation models such as Force Field Analysis or Change Kaleidoscope that will help give a broader perspective of the innovation project as has been recommended in the brief.

Critical Analysis of Data: The proposed approach is mainly focused on critical analysis rather than depiction of the subject matter (Kok and Siripipatthanakul, 2023). In the case, it should contemplate with criticality the assumptions made. For example, the gradual growth of revenues, and the constant costs of operations would be plausible.

Financial Justification for Innovation: The over £5,541 million positive NPV as calculated above provides strong financial support for trying this new concept (English 2022). Here it shows how the funding of innovation as an asset, can lead to massive amounts of business value and the shift from negative net income to positive.

Innovation and Risk: Even though innovative projects are generally associated with higher risk, the measures exceeding 50%, IRR (69.71%) and the payback period less than 3 years indicate that the Project could bring high profitability. This was expected given that disruptive innovations are generally high risk-high reward.

Scaling Innovation: The rise in the end, the annual cash flows deployed in the business calculation range from £1,500,000 of year one up to £3,500,000 of year five, captures the possibility of the AI-Diagnostix innovation (Bakar et al. 2020). The scalability of this technology is a feature that is typical of any successful technological disruption.

Innovation Adoption Curve: As to the value3, it could be associated with the innovation adoption curve with the growth of the revenue. The first one indicates a possible shift of early adopters in healthcare markets to the early majority.

Investment in Continuous Innovation: The constant operational cost in the calculation £1,000,000 per year could be essential R & D expenditure. This is in line with the ever changing world to enhance the production of best results in the field of artificial intelligence and health care.

2.2 Recommendation

From the above discussion, it is recommended that, for the viability of finance enhancement, and TechInnovate Ltd’s Ai Diagnostic project success, external funding, or strategic partnership is needed to be secured to decrease the gap of £3 million that is needed for completion. The venture capital exploration needs to be done, with government grants, or healthcare-focused investors, who can provide the required capital without the debt increase. In addition to that, Lean, and Just-in-time production methods are needed to be implemented for the inefficiencies reduction, and waste minimization in operations. This ensures that the project stays within budget, and on track. It is also recommended that regulatory experts' engagement is needed to be done in the early stage, which can mitigate delays in required approvals obtaining, and this ensures smoother entry into the market.

2.3 Change Plan

For TechInnovate, the change plan should prioritize addressing both challenges in operation, and challenges in finance (Smith 2021). At first, the external acquisition of funding will be managed by a dedicated task force within three months. Secondly, internal reconstruction is going to be done regarding the organization, by adopting Lean methodology for the allocation of resource improvement, and management of the project, with a six-month targeted timeline for implementation (Helman 2023). A regular affairs team simultaneously will be set to liaise with EMA, MHRA, and UK Medicines. In this regard, it is aimed to obtain all required certifications before the launch of product. Regular assessment of the product, which for every two months is set, will track the changes' effectiveness, and their alignment with the goals of the project.

3. Reflections

The journey of Techninnovate towards innovation highlights the major balance between reward and risk in the technology sector of healthcare. The AI diagnostic of this company shows the potential for diagnostic revolution and disruptive innovation. However, major regulatory, and financial challenges needed management carefully. This shows, in this regard, the strategic funding importance, operations streamlining, and early regulatory engagement. These are emphasized also majorly in this regard. The demonstration is also done regarding the technological innovations' long-term benefits, in profit, and in practices of healthcare transformation with patient outcomes. The way is paved through this for continued leadership in the industry.

Reference list

Journals

• Astuti, N.K., 2024. Exploring the Essence of Indonesian Securities-Based Crowdfunding. Int'l JL Changing World, 3, p.53.
• Bakar, N.M.A., Yasin, N.M. and Bakar, N.H.A., 2020. The Contemporary Role of Tabung Haji Malaysia in Fulfilling Sustainability via Islamic Social Finance. Journal of Islamic Finance, 9(2), pp.59-69.
• Baliouskas, P., Llopis, J., Gasco, J. and Gonzalez, R., 2023. Implementing turnaround strategies as an entrepreneurial process. International Entrepreneurship and Management Journal, 19(4), pp.2037-2063.
• Bulman, D.J., Yan, X. and Zhang, Q., 2022. Picking losers: How career incentives undermine industrial policy in chinese cities. The Journal of Development Studies, 58(6), pp.1102-1123.
• Carmody, P. and Wainwright, J., 2022. Contradiction and restructuring in the Belt and Road Initiative: reflections on China’s pause in the ‘Go world’. Third World Quarterly, 43(12), pp.2830-2851.
• Carver, L., 2023. Seeing no net loss: Making nature offset-able. Environment and Planning E: Nature and Space, 6(4), pp.2182-2202.
• Chua, C., 2023. Disruption from above, the middle and below: Three terrains of governance. Review of International Studies, 49(1), pp.37-52.
• English, J., 2022. Getting Off Track: the Northeast Corridor Improvement Project in an International Context. The Journal of Transport History, 43(1), pp.107-130.
• Griffith-Jones, S. and Naqvi, N., 2020. Industrial policy and risk sharing in public development banks: Lessons for the post-COVID response from the EIB and EFSI (No. 143). GEG Working Paper.
• Helman, L., 2023. Innovation Funding and the Valley of Death. SMU L. Rev., 76, p.263.
• Hermes, N. and Lensink, R., 2020. Microfinance and development. In Contemporary issues in development finance (pp. 51-72). Routledge.
• Hildyard, N., 2021. “Infrastructure” and the Big 4: Public–Private Partnerships, Corridors, and the Expansion of Capital. Professional Service Firms and Politics in a Global Era: Public Policy, Private Expertise, pp.197-215.
• Irtyshcheva, I., Stehnei, M., Popadynets, N., Levkovska, L. and Topchiy, A., 2022. Evaluation of the Efficiency of the Housing and Utilities Sector and Management of its Investment Framework in Conditions of Authorities Decentralization.
• Islam, M., Mukherjee, D., Chatterjee, R. and Mitra, S., 2022. A Self-Reliant Tea Economy Offering Inclusive Growth: A Case of Tripureswari Tea, India. Agronomy, 12(12), p.2935.
• Junaid Ashraf, M., Muhammad, F. and Hopper, T., Accounting signifiers, political discourse, popular resistance and legal identity during Pakistan Steel Mills attempted privatization.
• Kannan, K.P., 2023. Revisiting the Kerala ‘model’of development: a sixty-year assessment of successes and failures. The Indian Economic Journal, 71(1), pp.120-151.
• Khianthongkul, K. and Bunyavejchewin, P., 2024. Airport development projects in Thailand: a case study of Betong International Airport. Cogent Social Sciences, 10(1), p.2367260.
• Kok, S.L. and Siripipatthanakul, S., 2023. Strategic Management: The Case of Malaysian Airports Holdings Berhad (MAHB).
• Mukherjee, A., Sarma, A.P., Barah, A. and Mohan, A., 2020. Public sector enterprises in India: Enhancing geo-strategic reach and exports (No. 388). Working Paper.
• Mukherjee, B.B., 2022. Rising State Capitalism. World Affairs: The Journal of International Issues, 26(3), pp.10-27.
• Müller, M., Gogishvili, D. and Wolfe, S.D., 2022. The structural deficit of the Olympics and the World Cup: Comparing costs against revenues over time. Environment and Planning A: Economy and Space, 54(6), pp.1200-1218.
• Papko, A. and Kozarzewski, P., 2020. The evolution of Belarusian public sector: From command economy to state capitalism?. CASE Research Paper, (12).
• Prathapagiri, V.G. and Upadhayay, V., 2023. Privatization and Public Sector Sustainability. In Governance as a Catalyst for Public Sector Sustainability (pp. 200-221). IGI Global.
• Rishad, M., 2020. Corruption Circle of Sri Lanka: The Second Largest Enemy to the State.
• Smith, S.E., 2021. The characterisation for South African taxation purposes of gains and losses arising from the use of equity financial derivative instruments.
• Szyszczak, E., State aid, public funding and infrastructure: Case C-288/11 P Mitteldeutsche Flughafen AG, Flughafen Leipzig-Halle GmbH, established in Leipzig European Commission (‘Leipzig-Halle’)[2012].
• Tokel, M.K., 2022. The making and unmaking of the Zonguldak Coal Basin:| deindustrialization as a process.
• Vasudevan, S., 2022. Are Banking Institution reluctant to realise their losses?–An Irish perspective (Doctoral dissertation, Dublin, National College of Ireland).
• Westbrook, A.D., 2020. We ('re) Working on Corporate Governance: Stakeholder Vulnerability in Unicorn Companies. U. Pa. J. Bus. L., 23, p.505.
• Wilkins, S., 2020. Two decades of international branch campus development, 2000–2020: A review. International Journal of Educational Management, 35(1), pp.311-326.

Author Bio

Casey Bennett   7 years | PhD

My name is Casey Bennett and I have obtained my graduation, post-graduation and PhD from London Business School. I have been giving education to students for the last 7 years in the United Kingdom. I can help you deal with complex dissertation topics, assignments, and essays and finish them fast.